Immunotherapy with nivolumab in metastatic renal cell carcinoma in resource constraint settings: Impact of increasing intervals between standard doses, and stopping treatment early in responding patients.

Amit Rauthan,Poonam Patil,Nitin Yashas,S S Kulkarni,T Sood,Gaurav Nigade,S. P. Somashekhar,Shabber Zaveri

Immunotherapy with nivolumab in metastatic renal cell carcinoma in resource constraint settings: Impact of increasing intervals between standard doses, and stopping treatment early in responding patients.

2019

Amit Rauthan
Poonam Patil
Nitin Yashas
S S Kulkarni
T Sood
Gaurav Nigade
S. P. Somashekhar
Shabber Zaveri

e16078Background: Nivolumab is now a standard 2nd line treatment for patients of metastatic Renal cell cancer (mRCC) who progress on 1st line Sunitinib or Pazopanib. Most western centers use Nivolu...

Keywords:

Nivolumab
Renal cell carcinoma
Immunotherapy
Oncology
Pathology
Medicine
Internal medicine
resource constraints
Metastatic renal cell cancer
Sunitinib
Pazopanib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations